Valuation: Theralase Technologies Inc.

Market Cap 5.43Cr 3.84Cr 3.37Cr 3.19Cr 2.89Cr 368.16Cr 5.47Cr 38Cr 15Cr 187.87Cr 14Cr 14Cr 603.7Cr P/E 2026 *
-17.5x
P/E 2027 * 8.75x
Enterprise Value 5.43Cr 3.84Cr 3.37Cr 3.19Cr 2.89Cr 368.16Cr 5.47Cr 38Cr 15Cr 187.87Cr 14Cr 14Cr 603.7Cr EV / Sales 2026 *
69.1x
EV / Sales 2027 * 1.6x
Free-Float
79.6%
Yield 2026 *
-
Yield 2027 * -
1 week-5.41%
Current month-2.78%
1 month-2.78%
3 months-25.53%
6 months-35.19%
Current year+6.06%
1 week 0.17
Extreme 0.17
0.18
1 month 0.17
Extreme 0.17
0.2
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 29/06/2023
Director of Finance/CFO - 27/06/2019
Chief Executive Officer - 15/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 01/01/2008
Director/Board Member - 27/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Option

Director

3,360 0.0011%
27/08/26 Buy

Chief Executive Officer

42,000 0.0142%
24/08/26 Option

Chief Financial Officer

29,000 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.41%-7.89%-20.45% 3.84Cr
0.00%-1.72%+46.38%+84.20% 143.67Cr
-0.96%-7.62%-19.28%-43.72% 5.04Cr
Average -0.32%-5.13%+6.40%+6.68% 50.85Cr
Weighted average by Cap. -0.03%-3.43%+42.84%+77.34%

Financials

2026 *2027 *
Net sales 8L 6L 5L 5L 4L 5.33Cr 8L 55.25L 21.34L 2.72Cr 20.83L 20.38L 8.73Cr 3.39Cr 2.39Cr 2.1Cr 1.99Cr 1.8Cr 229.62Cr 3.41Cr 24Cr 9.2Cr 117.17Cr 8.98Cr 8.79Cr 376.52Cr
Net income -41.24L -29.11L -25.6L -24.21L -21.96L -28Cr -41.48L -2.9Cr -1.12Cr -14Cr -1.09Cr -1.07Cr -46Cr 69.01L 48.71L 42.84L 40.51L 36.75L 47Cr 69.41L 4.85Cr 1.87Cr 24Cr 1.83Cr 1.79Cr 77Cr
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
28/26/28 CA$0.1750 0.00% 63,849
25/26/25 CA$0.1750 0.00% 71,411
24/26/24 CA$0.1750 0.00% 76,608
23/26/23 CA$0.1750 -2.78% 81,078
22/26/22 CA$0.1800 -2.70% 3,06,004
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1750CAD
Average target price
0.7000CAD
Spread / Average Target
+300.00%

Quarterly revenue - Rate of surprise